Immunocore Holdings UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Hello, everyone. My name is Dina Al-Manchet, one of the biotech analysts here at UBS, and I am excited and pleased to welcome Travis Coy, Chief Financial Officer of Immunocore. I am excited for us to get started on this. Maybe we can start with a couple of questions around the commercial business for KIMMTRAK.
Maybe just, we are probably in our fourth year of launch now, given pretty peak penetration levels in especially OUS market and maybe 70% in the U.S., nearly there. So, maybe just thinking about where are there remaining growth drivers, particularly in the community setting, both in the U.S. and OUS, and where do you see KIMMTRAK from here in the outer years?
Yeah. No, thanks, Dina. First of all, thank you for having me.
Of course. Appreciate you having us.
All good questions on KIMMTRAK. We are really pleased that KIMMTRAK has become the standard of care across all major markets. You are elaborating to some of the penetration levels we have. We are at 70% plus penetration across all markets. As we look at the growth, naturally in this part of the product's life cycle, we are seeing growth begin to moderate. It is a good thing, right? We did a good job on launch, right?
You launched very quickly. Yeah.
We still see opportunities for growth. There are two different aspects. There is the U.S. and the OUS. From a U.S. perspective, growth is centered and focused on penetrating further into that community setting, continue to increase patient access in that community setting. OUS, our growth mainly comes from new launches. We are 80% to 90% penetrated in some of those markets, so new launches are really where we see the growth. Again, it is increasing that patient access. We also see some growth OUS from increasing duration of therapy. Some of the markets where we have more recently launched, that duration of therapy is still ticking up to where it already is in established markets.
Okay. That makes sense. What is the duration of therapy now? I think the last time we talked about this, maybe around 14 months. What is it looking like now in nearly 2027?
Yeah. So, I'll mention, we are five years on the market now.
Yes By the way, that's okay.
So, as we look at the duration of therapy, in the U.S., it's mostly stabilized.
Okay. I'd say it's fair to say across the major markets where we've been launched.
Yep Four or five years.
Yep we mostly see the duration of therapy around 14 months.
Okay. What is remarkable about that is, in the clinical setting, we saw around 10 to 11 months.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
